Cancer antigen 19-9 (CA 19-9) is a type of tumor marker. Antigens are substances that cause the immune system to respond. Pancreatic cancer cells can release CA 19-9 into the body.

A Tumor Marker Ca 19-9 In Diabetics Can Lead To Misdiagnosis Of Pancreatic Cancer, Study Suggests. ScienceDaily. Retrieved June 4, 2025 from www.sciencedaily.com / releases / 2007 / 10 ...

Tumor markers are made by cancer cells or produced ... A 2018 review compared the utility of measuring CA19-9 and CEA in diagnosing pancreatic cancer. Overall, CA19-9 had a higher sensitivity than ...

CA19-9 is the most widely used pancreatic cancer serum markers. Its level has been shown to correlate with the TNM staging and the tumor sizes in patients with pancreatic cancer.

CA 19-9 and CEA are used as additional tumor markers with poor sensitivity. In 2000, we were able to show a superior diagnostic sensitivity of Tumor M2-PK as compared with the established CA 19-9 ...

Phase II Trial of Chronomodulated Infusion of High-Dose Fluorouracil and l-Folinic Acid in Previously Untreated Patients With Metastatic Colorectal Cancer PURPOSE: This phase II, multicenter, ...

However, when Camidge and colleagues examined levels of four markers classically associated with other cancers, namely CEA, CA125, CA19.9 and CA27.29, they found that if all four were checked, at ...

To investigate the prognostic value of quality of life (QOL) relative to tumour marker carbohydrate antigen (CA) 19-9, and the role of CA 19-9 in estimating palliation in patients with advanced ...

A research group from Turkey has found that the use of a tumor marker, Ca 19-9, in diabetics with a standard reference value can lead to misdiagnosis of pancreatic cancer. Advanced Search.